The core problem is one that has haunted nanomedicine since its inception. Laboratory results routinely show dramatic tumour accumulation and tumour shrinkage in mice, but clinical translation has remained stubbornly limited. The review attributes this gap primarily to the physical inaccessibility of tumour tissue. Solid tumours are not simply masses of malignant cells; they are mechanically abnormal environments. Their extracellular matrix (ECM) — the dense network of collagen, hyaluronan and other structural proteins that surrounds cells — becomes progressively densified and stiffened as the tumour grows. This matrix cross-linking exerts elevated solid stress on the tumour mass, compressing blood and lymphatic vessels and creating pockets of high interstitial fluid pressure (IFP) that push outward against anything trying to enter.

The consequence is a transport-limiting system. Blood vessels inside tumours are dysfunctional, leaky and irregularly shaped, so drug-bearing nanoparticles that escape into the bloodstream often exit through the wrong vessels or fail to exit at all. Those that do reach tumour tissue face a dense ECM that slows diffusion to a crawl, while elevated IFP suppresses the convective flow that normally carries macromolecules through tissue. The result is heterogeneous intratumoral distribution: drugs pool near the periphery of the tumour, close to blood vessels, while the tumour core — often the most hypoxic and aggressive region — remains untouched. Classic mathematical models of tumour transport, dating back to work by Baxter and Jain in the late 1980s, and decades of experimental work since, have established that this physical architecture, not just molecular targeting, determines whether a therapeutic payload reaches its target.

Singh’s review reframes nanomedicine failure as a transport-limited problem in which physical constraints are dominant — though not exclusive — determinants of therapeutic outcome. The framework categorises mechanotherapeutic strategies into three complementary approaches, each targeting a different aspect of the tumour’s mechanical armour.

The first category comprises stiffness-modulating systems that remodel the ECM itself. Enzymatic degradation of hyaluronan, collagen-targeting agents and matrix-loosening drugs have all demonstrated the ability to soften the tumour stroma and reduce diffusion distances. Landmark work on pancreatic ductal adenocarcinoma, one of the most fibrotic and drug-resistant cancers, showed that enzymatic targeting of the stroma could ablate physical barriers to treatment entirely. The review emphasises that these approaches must be carefully titrated: complete depletion of carcinoma-associated fibroblasts or wholesale matrix destruction can paradoxically accelerate tumour progression and induce immunosuppression, as has been demonstrated in pancreatic cancer models. The goal is controlled remodelling — enough softening to enable drug penetration without destabilising the tumour’s immunological containment.

The second approach involves deformable and penetration-optimised materials engineered to navigate structural constraints rather than brute-force through them. Particle size is a critical variable: sub-100-nanometre polymeric micelles accumulate in poorly permeable tumours in a size-dependent manner, and studies of size-shrinkable nanosystems show that designs capable of transitioning from larger accumulation-optimised particles to smaller penetration-optimised ones can achieve both high tumour retention and deep tissue infiltration. Particle shape and elasticity matter equally. Soft, deformable nanoparticles can squeeze through narrow interstitial gaps that rigid particles of equivalent diameter cannot traverse, and recent work quantifying size-dependent penetration depth of colloidal nanoparticles into cell spheroids confirms that mechanical pliability directly correlates with delivery depth. Singh argues that biomaterial design should explicitly incorporate mechanical properties — not just surface chemistry — as a design axis.

The third category addresses pressure and perfusion. Pressure-alleviating strategies aim to lower IFP, restoring the transvascular and interstitial pressure gradients that drive convective drug transport. Vessel-normalising approaches, rooted in the pioneering work of Jain and colleagues, use anti-angiogenic agents in carefully timed regimens to prune the chaotic, poorly functional tumour vasculature into something resembling normal tissue — a window during which perfusion improves, hypoxia drops, and nanoparticles can actually reach the tumour interior. Combined strategies that simultaneously reduce solid stress and normalise vasculature have shown synergistic improvements in drug delivery and, importantly, in immunotherapy response, since better-perfused tumours are more accessible to immune cells.

What distinguishes this review from previous transport-focused discussions is its extension into mechanochemical coupling — the molecular machinery by which mechanical stress is translated into redox and metabolic adaptation within tumour cells. Singh identifies a representative signalling axis composed of reactive oxygen species (ROS), AMP-activated protein kinase (AMPK), and sirtuin 1 (SIRT1). Mechanical stress within the tumour microenvironment modulates ROS production, which in turn influences AMPK, the cell’s primary energy sensor, and SIRT1, a NAD+-dependent deacetylase that governs metabolic adaptation under stress. This axis links the physical state of the tumour to its metabolic and oxidative resilience, offering a molecular handle for responsive biomaterial design: materials could, in principle, be engineered to sense and modulate this signalling cascade in tandem with their delivery function, turning mechanical intervention into a coordinated biochemical one as well.

The framework also incorporates microdevice-enabled platforms as an experimental backbone. Microfluidic and tumour-on-chip systems allow researchers to recreate the tumour microenvironment — including ECM density, interstitial flow, solid stress and vascular geometry — under quantitatively controllable conditions. Vascularised cancer-on-chip models have demonstrated how perfusion directly affects tumour spheroid growth and drug delivery, while tumour-microenvironment-on-chip systems can simulate complex nanoparticle transport around tumours. Implantable microdevices capable of performing high-throughput in vivo drug sensitivity testing directly within tumours further bridge the gap between bench and bedside. Together, these platforms provide a quantitative and experimentally tractable way to evaluate transport behaviour and optimise delivery strategies before clinical translation.

The translational implications are significant. Imaging biomarkers such as elastography — an emerging branch of medical imaging that maps tissue stiffness non-invasively — could potentially be used to stratify patients by tumour stiffness, guiding which mechanotherapeutic interventions and biomaterial designs are most appropriate for a given tumour. The review notes that solid stress and elastic energy have been proposed as quantitative measures of tumour “mechanopathology,” opening the door to a precision mechanomedicine approach in which the mechanical phenotype of a patient’s tumour directly informs therapeutic strategy.

Singh is careful to frame the framework as physically informed and experimentally actionable rather than a complete solution. Physical constraints are described as dominant but not exclusive determinants of therapeutic outcome, and the review acknowledges that molecular resistance, tumour heterogeneity and immune evasion remain formidable challenges that no single strategy can address alone. The value of the mechanotherapeutic framework lies in its integration: by treating mechanics, transport, redox biology and metabolic signalling as a coupled system rather than isolated problems, it offers biomaterials designers a unified design language.

The review is published as Singh, F., “Mechanotherapeutic biomaterials: Overcoming physical barriers to enhance intratumoral drug delivery in solid tumours,” in Biomedical Microdevices, volume 28, article 51. As cancer nanomedicine enters its next phase of clinical translation, the message from this work is clear: the next generation of cancer therapeutics will need to be built not only with molecular precision but with mechanical intelligence — materials designed to soften the tumour’s scaffolding, squeeze through its corridors, relieve its internal pressures and, ultimately, deliver on the promise that nanomedicine has been chasing for three decades.

The innovative concept hinges on the versatility of DNA as a structural molecule. By strategically folding double-stranded DNA into predetermined nanostructures — a technique known as DNA origami — scientists created molecular scaffolds that can carry fluorescent dyes or even anticancer drugs. This molecular origami confers precision at an unprecedented scale, enabling the delivery of imaging agents directly to malignant tissues with minimal interference to surrounding healthy cells. Doing so not only promises to refine tumor visualization during surgery but also opens avenues for targeted chemotherapy with reduced systemic toxicity.

To simulate the complex microenvironment of pancreatic tumors, the research team employed advanced 3D-printed tumoroids coupled with microfluidic tumor-stroma models. These systems replicate the dense stromal architecture intrinsic to pancreatic cancer, providing a refined in vitro platform that diminishes dependence on animal models and accelerates therapeutic validation. The DNA origami structures, infused with imaging dyes, demonstrated remarkable selectivity when introduced to these tumoroids, manifesting robust uptake by KRAS-mutant cancer cells while sparing normal pancreatic tissue.

Beyond the synthetic tumor models, the researchers extended their investigation to in vivo murine models embedded with human pancreatic tumor grafts. Here, fluorescence imaging tracked the biodistribution of the DNA origami nanostructures, affirming their preferential accumulation within malignant tissue. This dual-model approach substantiates the biological relevance and translational potential of DNA origami in clinical oncology, moving one step closer to real-world applications in cancer diagnostics and treatment.

A critical discovery within the study was the influence of the physical parameters of the DNA nanostructures on cellular uptake. The team compared tube-shaped and tile-shaped DNA origami configurations at varying sizes, noting that tube-shaped structures approximately 70 nanometers in length and 30 nanometers in diameter exhibited optimal uptake by pancreatic cancer cells. Smaller tubes around 6 nanometers long and the same diameter also showed significant accumulation. Conversely, larger tubes and all tested tile-shaped molecules failed to replicate this efficient targeting. This observation underscores the intricate interplay between nanostructure morphology and cellular internalization mechanisms.

Professor Bumsoo Han, leading the research, expressed surprise at these findings, emphasizing that uptake is governed by an optimal “sweet spot” in both size and shape that facilitates selective penetration into cancerous cells without affecting normal tissue. This revelation challenges previous assumptions that smaller size uniformly enhances uptake and spotlights the need for precision engineering in the development of nanomedicines.

Looking forward, the research sets the stage for the next generation of therapeutics employing DNA origami as delivery vehicles. By loading these nanoscale frameworks with chemotherapy agents, it is conceivable to administer treatments that concentrate drug effects solely on cancer cells, thereby sparing healthy tissue and reducing adverse side effects. The integration of sophisticated tumor models aims to expedite drug discovery cycles while minimizing reliance on animal testing, aligning with ethical advancements in biomedical research.

The implications of this breakthrough extend beyond pancreatic cancer, heralding a paradigm shift in how molecular imaging and targeted therapy might be approached in various malignancies characterized by dense tumor microenvironments. The precision and programmability of DNA origami nanostructures render them ideally suited for bespoke applications tailored to diverse genetic and anatomical tumor profiles.

This research also highlights the collaborative synergy between engineering and biomedical sciences. By merging mechanical engineering expertise with oncology-focused bioengineering, the team crafted a multidisciplinary strategy that leverages nanoscale manipulation, advanced modeling, and molecular biology to tackle one of medicine’s most intractable diseases. The involvement of prominent facilities like the Carl R. Woese Institute for Genomic Biology and the Beckman Institute underscores the confluence of cutting-edge technology driving this innovation.

Published in the journal Advanced Science, these findings mark a significant stride forward in the molecular imaging field. The study provides robust preclinical evidence that DNA origami can revolutionize how imaging agents and drugs are delivered with cellular and tissue specificity. If translated successfully into clinical practice, such technology could enhance surgeons’ ability to delineate tumor boundaries with exquisite clarity and administer localized chemotherapy with enhanced efficacy.

Moreover, the deployment of 3D printing and microfluidics to engineer tumoroids sets a new standard for modeling human cancers ex vivo. These techniques allow researchers to deconstruct and replicate intricate tumor-stroma interactions in a controlled environment, fostering rapid hypothesis testing and therapeutic optimization. This is particularly valuable in diseases like pancreatic cancer, where traditional models have fallen short in mimicking the fibrotic milieu that impairs drug penetration.

Funding from the National Institutes of Health and the National Science Foundation has been instrumental in supporting this endeavor. Such backing also emphasizes the prioritization of interdisciplinary research initiatives that merge nanotechnology, oncology, and engineering to confront complex health challenges. Professor Han, alongside collaborators at Purdue and affiliated research institutes, continues to pioneer advancements aimed at refining diagnostic precision and therapeutic targeting through nanoscale design.

The clinical translation of DNA origami technology promises a future where pancreatic cancer patients might benefit from enhanced surgical outcomes and tailored chemotherapy regimens with fewer side effects. While early-stage, this research lays the groundwork for innovative therapies that exploit molecular self-assembly principles to overcome existing barriers in cancer care.

As the research community eagerly anticipates further developments, the extraordinary specificity and versatility of DNA origami nanostructures stand as a beacon for the future of precision medicine. Their capacity to interface at the molecular level with diseased cells, combined with the adaptability to carry diverse functional cargoes, positions them as a transformative tool in the battle against pancreatic and other aggressive cancers.

Subject of Research: Cells

Article Title: DNA origami-cyanine nanocomplex for precision imaging of KRAS-mutant pancreatic cancer cells

News Publication Date: 14-Feb-2025

Web References:
https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202410278

References:
Han, B., Choi, J.H., et al. “DNA origami-cyanine nanocomplex for precision imaging of KRAS-mutant pancreatic cancer cells.” Advanced Science, DOI: 10.1002/advs.202410278.

Image Credits:
Photo by Fred Zwicky

Keywords: Pancreatic cancer, DNA origami, KRAS mutation, fluorescent imaging, nanotechnology, tumor microenvironment, 3D tumoroids, microfluidics, targeted therapy, molecular imaging, nanomedicine, tumor-stroma model

Esophageal cancer remains one of the most lethal malignancies worldwide, owing largely to its late diagnosis and aggressive metastatic behavior. Central to cancer metastasis is the basement membrane, a specialized extracellular matrix layer instrumental in maintaining tissue architecture and influencing cellular behavior. While prior research has highlighted its general importance, the exact molecular constituents and their prognostic utility in esophageal carcinoma have remained elusive—until now.

The investigative team embarked on a comprehensive analysis incorporating 152 esophageal cancer specimens alongside 11 normal esophageal tissue samples. Employing cutting-edge differential gene expression profiling and state-of-the-art statistical techniques such as Least Absolute Shrinkage and Selection Operator (LASSO) regression, they distilled a robust six-gene signature tightly linked to basement membrane components. These genes—LAMC2, GPC2, AGRN, ITGA3, LAMA3, and LOXL4—emerged as potent prognostic markers, each contributing uniquely to tumor progression dynamics.

To translate these molecular insights into clinically actionable tools, researchers integrated the six-gene panel with traditional clinical parameters via a nomogram—a graphical calculation tool widely used in medical prognosis. This fusion enabled a personalized risk stratification framework capable of predicting overall survival rates with enhanced accuracy. Such integration underscores a pivotal shift toward multi-dimensional prognostic models in oncology, where molecular signatures complement clinical observations.

Delving deeper, the team harnessed bioinformatic algorithms to profile the tumor microenvironment’s immune landscape across varying risk categories determined by the gene panel. Notably, distinct patterns of immune cell infiltration were observed between high-risk and low-risk patient groups, illuminating the interplay between basement membrane alterations and immune modulatory mechanisms within the esophageal tumor niche. These findings pave the way for exploring immune-targeted therapies tailored according to basement membrane gene expression patterns.

Parallel to immune profiling, analyses of chemotherapeutic sensitivity underscored differential drug responsiveness in stratified risk groups. This revelation promises to refine therapeutic regimens by aligning treatment modalities with molecularly defined patient subsets, potentially mitigating the high attrition rates in conventional chemotherapy outcomes for esophageal cancer.

Crucially, the study transcended in silico predictions through rigorous experimental validation. Immunohistochemical assays confirmed pronounced overexpression of the identified six genes within esophageal tumor tissues, strengthening their candidacy as biomarker targets in clinical practice. Such protein-level validation is indispensable for bridging the gap between genomic findings and tangible medical applications.

Further mechanistic exploration utilized KYSE-150 esophageal squamous carcinoma cell lines to dissect the functional roles of each gene. Gene silencing experiments revealed a nuanced architecture of tumor cell behavior: knockdown of LAMC2 significantly impeded cellular migration, indicative of its pro-metastatic influence. Conversely, suppression of AGRN, GPC2, ITGA3, LAMA3, and LOXL4 paradoxically enhanced migratory capacity, suggesting complex regulatory feedback within the tumor microenvironment.

Complementary proliferation assays illuminated additional layers of gene functionality, with inhibition of GPC2, ITGA3, and LAMA3 leading to accelerated cancer cell growth. These observations intimate that these basement membrane genes not only orchestrate metastatic potential but also modulate proliferative vigor, thereby dictating tumor aggressiveness through multifaceted molecular pathways.

The synthesis of computational modeling, clinical correlation, and laboratory experimentation culminated in the establishment of a basement membrane-derived risk signature—a novel prognostic apparatus poised to revolutionize esophageal cancer management. By finely categorizing patients according to molecular risk, this model empowers clinicians to craft individualized surveillance and treatment protocols, optimizing therapeutic efficacy.

Beyond prognostication, this research illuminates prospective molecular targets for drug development. Modulating the expression or activity of these six basement membrane-related genes could yield innovative therapeutic avenues, potentially curbing tumor dissemination and improving survival rates in esophageal cancer patients.

This work exemplifies the synergy of integrative omics and functional biology, spotlighting how basement membrane dynamics are inextricably linked with tumor progression. The elucidation of these intricate gene networks enhances our understanding of esophageal cancer biology and fosters precision medicine paradigms customized to molecular tumor profiles.

Future investigations may expand upon these findings by exploring the interplay of basement membrane regulators with other tumor microenvironmental factors, including stromal cells and signaling cascades. Such holistic comprehension could refine prognostic accuracy and unearth new intervention strategies that transcend current therapeutic limitations.

In essence, this model heralds a new era in esophageal oncology research, where basement membrane constituents serve as both prognostic sentinels and therapeutic targets. Its clinical translation could transform patient care, enabling earlier intervention and bespoke treatments that markedly improve outcomes against this formidable disease.

As esophageal cancer continues to challenge the medical community, the integration of biomarker-driven risk modeling and functional validation paves a promising path forward. The collective efforts by Xu, Wang, and their colleagues mark a significant leap toward unraveling the molecular complexity of esophageal carcinoma and tailoring its management with unprecedented precision.

The study’s comprehensive approach—merging bioinformatics, immune profiling, drug sensitivity analyses, and cellular biology—provides a robust framework encouraging similar multidimensional investigations across other aggressive cancers. Such endeavors will likely accelerate the advent of next-generation diagnostic and therapeutic tools, marking milestones in oncology’s battle against metastatic disease.

In conclusion, this innovative basement membrane-related gene signature not only enhances prognostic capabilities but also enriches the understanding of esophageal cancer’s molecular underpinnings. It stands as a testament to the power of integrated research strategies in combating cancer and offers tangible hope for affected patients worldwide.

Subject of Research: Basement membrane-related regulators as prognostic biomarkers and functional modulators in esophageal cancer.

Article Title: A model of basement membrane-related regulators for prediction of prognoses in esophageal cancer and verification in vitro.

Article References:
Xu, L., Wang, B., Wang, C. et al. A model of basement membrane-related regulators for prediction of prognoses in esophageal cancer and verification in vitro. BMC Cancer 25, 696 (2025). https://doi.org/10.1186/s12885-025-14081-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14081-4